

# Cytotoxicity on human cells of Cry1Ab and Cry1Ac Bt insecticidal toxins alone or with a glyphosate-based herbicide

R. Mesnage,<sup>a,b</sup> E. Clair,<sup>a,b</sup> S. Gress,<sup>a,b</sup> C. Then,<sup>c</sup> A. Székács<sup>d</sup> and G.-E. Séralini<sup>a,b,\*</sup>

**ABSTRACT:** The study of combined effects of pesticides represents a challenge for toxicology. In the case of the new growing generation of genetically modified (GM) plants with stacked traits, glyphosate-based herbicides (like Roundup) residues are present in the Roundup-tolerant edible plants (especially corns) and mixed with modified Bt insecticidal toxins that are produced by the GM plants themselves. The potential side effects of these combined pesticides on human cells are investigated in this work. Here we have tested for the very first time Cry1Ab and Cry1Ac Bt toxins (10 ppb to 100 ppm) on the human embryonic kidney cell line 293, as well as their combined actions with Roundup, within 24 h, on three biomarkers of cell death: measurements of mitochondrial succinate dehydrogenase, adenylate kinase release by membrane alterations and caspase 3/7 inductions. Cry1Ab caused cell death from 100 ppm. For Cry1Ac, under such conditions, no effects were detected. The Roundup tested alone from 1 to 20 000 ppm is necrotic and apoptotic from 50 ppm, far below agricultural dilutions (50% lethal concentration 57.5 ppm). The only measured significant combined effect was that Cry1Ab and Cry1Ac reduced caspases 3/7 activations induced by Roundup; this could delay the activation of apoptosis. There was the same tendency for the other markers. In these results, we argue that modified Bt toxins are not inert on nontarget human cells, and that they can present combined side-effects with other residues of pesticides specific to GM plants. Copyright © 2011 John Wiley & Sons, Ltd.

**Keywords:** Roundup; Bt toxins; Cry1Ab; Cry1Ac; GMOs; mixtures; glyphosate; human cells

## INTRODUCTION

The real effects of mixtures of chemical pollutants are a major concern for public health (Monosson, 2005). Humans are exposed to hundreds of compounds on a daily basis. The commercialized combinations could be a first matter of concern. Agricultural genetically modified organisms (GMOs) are steadily increasing worldwide, and they need to be carefully assessed (Séralini *et al.*, 2009, 2011; Spiroux de Vendômois *et al.*, 2010). Nowadays 99.9% of GMOs can be described as pesticide plants, designed for herbicide tolerance and/or modified insecticide production (James, 2010). Thus pesticides residues co-occur in the plant, synthesized by the plant itself, by the expression of the inserted transgene (modified Bt from *Bacillus thuringiensis*) or through external pesticide treatment facilitated by the transgene-dependent tolerance to herbicides (Roundup in most instances). In turn, such residues exert their effects upon consumption or release into the environment (Arregui *et al.*, 2004; Tank *et al.*, 2010). Owing to their key role in intensive agriculture, potential side effects of such combined pesticides residues should be assessed. *In vitro* tests are frequently recommended as a first step to replace animal models in toxicity studies. Here, we have tested for the first time the effects of Cry1Ab and Cry1Ac alone and combined with Roundup on human cells.

Modified toxins from Bt are Cry proteins forming pores in insect cell membranes (Then, 2010); they account for 39% of edible plant GMOs worldwide (James, 2010). Since natural Bt toxins have long been used, their modified counterparts are often compared with them. However, the latter derivatives are truncated,

adapted and modified synthetic sequences; consequently their activity is possibly quite different from the natural ones (Séralini *et al.*, 2011). Also, Bt toxins are claimed and believed to be safe. Yet prions, hormones and venoms are also proteins, and are far from being innocuous. To date, Bt toxins have not been tested on human cells. However, Bt corns are regularly consumed by humans in America and their residues have even been found in maternal and fetal cord serum at around 0.2 ppb (Aris and Leblanc, 2011), which does not take into account the tissue levels. Nontarget toxicity of natural Bt toxins has been detected in mammals, for instance at a 50% lethal concentration (LC<sub>50</sub>) from around 10 to 520 ppb (Ito *et al.*, 2004; Nagamatsu *et al.*, 2010; Rani and Balaraman, 1996).

Roundup formulations are mixtures of glyphosate and adjuvants such as ammonium sulfate, benzisothiazolone, glycerine, isobutane, isopropylamine, polyethoxylated alkylamines and

\*Correspondence to: G.-E. Séralini, University of Caen, Risk Pole MRSN-CNRS, Laboratory of Biochemistry EA2608, Esplanade de la Paix, 14032 Caen cedex, France. E-mail: criigen@unicaen.fr

<sup>a</sup>University of Caen, Risk Pole MRSN-CNRS, Laboratory of Biochemistry EA2608, Esplanade de la Paix, 14032 Caen cedex, France

<sup>b</sup>CRIIGEN, 40 rue de Monceau, 75008 Paris, France

<sup>c</sup>Testbiotech e.V., Frohschammerstr. 14, 80807 München, Germany

<sup>d</sup>Plant Protection Institute, Hungarian Academy of Sciences, H-1525, Budapest, POB 102, Hungary

sorbic acid (Cox, 2004). Glyphosate-based herbicides are the object of an increasing number of studies, which reveal, in combination with adjuvants, endocrine-disrupting effects, and tumor-promoting or teratogenic effects on numerous nontarget species (Gasnier *et al.*, 2009; George *et al.*, 2010; Paganelli *et al.*, 2010), for instance from 0.5 ppm on androgen receptors. We have used human embryonic kidney cell line HEK293 as a sensitive model (Benachour and Séralini, 2009). The kidney model was used also because a body of evidence suggests kidney dysfunctions as endpoints of GMO diet effects (Séralini *et al.*, 2011), and thus kidney cells could be a target for GMOs. We first measured the mitochondrial respiration level, by succinate dehydrogenase (SD) activity assessment in order to test cytotoxicity. Then, as *Bt* proteins act as pore forming toxins (Then, 2010), we determined adenylate kinase (AK) activity when released in the medium, revealing possible membrane alterations. In association, we assayed caspase 3 and 7 activities in order to separate the apoptotic and necrotic actions involved in cytotoxic effects. Moreover, human cell lines allow the study of unintended side effects on nontarget species of GMO-associated pesticides.

## MATERIALS AND METHODS

### Chemicals

Cry1Ab and Cry1Ac were prepared as described previously by two different laboratories (Székács *et al.*, 2010; Pusztai-Carey *et al.*, 1994). The glyphosate-based herbicide tested was commercially available Roundup® GT Plus formulation, approval no. 2020448 (Monsanto, Anvers, Belgium). It contains 450 g l<sup>-1</sup> glyphosate acid (*N*-phosphonomethyl-glycine). Successive dilutions were prepared in Eagle's modified minimum essential medium (EMEM; Abcys, Paris, France). 3-(4,5-Dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) and all other compounds were obtained from Sigma-Aldrich (Saint-Quentin Fallavier, France), unless specified. MTT was prepared as a 5 mg ml<sup>-1</sup> stock solution in phosphate-buffered saline, filtered through a 0.22 μm filter before use, and diluted to 1 mg ml<sup>-1</sup> in EMEM.

### Toxin Preparations

The Cry1Ab and Cry1Ac toxins are cloned from the natural *Bacillus thuringiensis* subspecies *kurstaki* HD-1 strain and expressed in *Escherichia coli* as single gene products. The inclusion bodies, containing the protoxins, were solubilized at pH 10.5 in the presence of β-mercaptoethanol and treated with commercial bovine trypsin (Sigma, USA). The 65 kDa activated toxins were isolated by ion exchange HPLC and the pure toxin fractions were desalted and lyophilized and stored at -80 °C. After storage, toxins were diluted in a 50 mM Na-carbonate-HCl buffer at 1 mg ml<sup>-1</sup> (pH 9.5), and then diluted in EMEM.

### Cell Lines

The human embryonic kidney 293 cell line (ECACC 85120602) was provided by Sigma-Aldrich (Saint-Quentin Fallavier, France). Cells were grown in phenol red-free EMEM (Abcys, Paris, France) containing 2 mM glutamine, 1% nonessential amino acid, 100 U ml<sup>-1</sup> of antibiotics (a mixture of penicillin, streptomycin and fungizone; Lonza, Saint Beauzire, France), 10 mg ml<sup>-1</sup> of liquid kanamycin (Dominique Dutscher, Brumath, France) and 10% fetal bovine serum (PAA, les Mureaux, France). Cells were grown at

37 °C (5% CO<sub>2</sub>, 95% air) during 24 h to 80% confluence, washed with serum-free EMEM and then exposed to various chemicals, since the serum delayed the cell necrosis by about 48 h in the presence of toxic compounds (Benachour *et al.*, 2007). The control cells grow normally in serum-free medium up to 96 h.

### Cell Treatments and Cytotoxicity Biomarkers


Cells at 80% confluence in 48- or 96-well plates (Dominique Dutscher, Brumath, France) were washed with serum-free EMEM, in order to avoid other combined effects, and then exposed to various concentrations of *Bt* toxins or Roundup GT Plus in EMEM serum-free medium for 24 h. *Bt* toxins were used from 10 ppb to 100 ppm (in the range of GM plant production). Concerning Roundup, 50% lethal concentrations (LC<sub>50</sub>) were assessed from 1 to 20 000 ppm (the latter is the agricultural dilution). Combined effects were measured by mixing LC<sub>50</sub> of Roundup with three doses of each *Bt* toxin. After treatments, the following tests were applied: mitochondrial respiration assay (MTT) through the succinate dehydrogenase activity measurement (Mosmann, 1983). The optical density was measured at 570 nm using a Mithras LB 940 luminometer (Berthold, Thoiry, France). The bioluminescent ToxiLight bioassay (Lonza, Saint Beauzire, France) was applied for the membrane degradation assessment, by the intracellular AK release in the medium; this is described as a necrosis marker (Crouch *et al.*, 1993). Finally, the apoptotic cell death was evaluated with the Caspase-Glo 3/7 assay (Promega, Paris, France). Luminescence was measured using a Mithras LB 940 luminometer (Berthold, Thoiry, France). These methods were previously described by our group (Benachour and Séralini, 2009).

### Statistical Analysis

The experiments were repeated at least three times in different weeks on three independent cultures (*n* = 9). LC<sub>50</sub> values were calculated by a nonlinear regression using a sigmoid (five-parameter) equation with the GraphPad Prism 5 software. All data were presented as the means ± standard errors (SEs). Statistical differences were determined by Student *t*-test using significance levels at *P* < 0.01 (\*\*\*) and *P* < 0.05 (\*).

## RESULTS

We measured for the first time cytotoxic effects of *Bt* toxins, alone or in combination with a glyphosate-based herbicide, on HEK293 cells. First of all, we confirmed that the buffer was not cytotoxic for the cells. The mitochondrial succinate dehydrogenase activity of treated cells significantly decreased at 100 ppm of Cry1Ab alone (by 11%, Fig. 1A). Even if it was limited, this phenomenon was undetected for Cry1Ac. Lower doses were tested from 10 ppb to 10 ppm, but significant effects were not observed. We obtained similar effects with a Cry1Ab toxin provided by another laboratory that was prepared and stored independently (Fig. 1A). We measured AK activity after its release in the medium in order to evaluate plasma membrane integrity. A concentration of Cry1Ab of 100 ppm increased AK leakage in the medium 2-fold, revealing plasma membrane alterations. This was performed for the two Cry1Ab toxins. Apoptotic effects of Cry1Ab and Cry1Ac by means of caspase 3/7 activities were studied; no effects on HEK293 cells were visible. We can therefore confirm that Cry1Ab can induce cytotoxic effects via a necrotic mechanism in these conditions at 100 ppm.




**Figure 1.** Cytotoxic effects of modified *Bt* toxins Cry1Ac and Cry1Ab on HEK293 cell line. (A) Cell death has been measured on mitochondrial succinate dehydrogenase after 24 h exposure to two Cry1Ab toxins up to 100 ppm prepared from different sources (A, black curves with circles and squares) and Cry1Ac (grey curve). (B) Cell membrane degradation was measured by adenylate kinase release (RU, relative units) provoked by Cry1Ab and Cry1Ac toxins (1–100 ppm) in comparison to control (C). No effect was detected on caspase 3/7 activities; therefore results are not displayed. Standard errors of the mean are indicated in all instances ( $n=9$ ; \*  $P < 0.05$ ).

Closer to the reality of exposure, we then tested combined effects of *Bt* toxins with Roundup (Fig 2). According to our previous results, Roundup is cytotoxic by inhibition of mitochondrial respiration activity, far below agricultural dilutions (around 200 times less) with an  $LC_{50}$  of 57.5 ppm (Fig. 2A). At this concentration, Roundup also induced necrosis evidenced by a 15-fold increase of an AK release. Apoptosis induction was measured by a 6.7-fold caspase 3/7 activities enhancement (Fig. 2B). However, concerning combined effects we observed significant effects on apoptosis; both *Bt* toxins from 10 ppm reduced caspase 3/7 activities (by around 50%) when they were induced in Roundup at its  $LC_{50}$  (Fig. 2B). Similarly, there was a non significant tendency for both toxins (data not shown) to reduce AK leakage and mitochondrial respiration inhibition induced by Roundup.

## DISCUSSION

Few studies have been performed on nontarget effects of *Bt* toxins, and none with modified *Bt* toxins extracted from plants, or together with Roundup residues, even in regulatory files. For natural *Bt* toxins, their mechanisms of action and insect resistance are not fully understood (Singh and Sivaprasad, 2009), and the metabolism of these proteins in mammals is unknown (Séralini *et al.*, 2011; Chowdhury *et al.*, 2003). They may even interact with extrinsic factors (Then, 2010). Billions of people and wildlife could be exposed to modified *Bt* toxins; therefore understanding their potential side effects is crucial.



**Figure 2.** Effects of Roundup alone and with modified *Bt* toxins Cry1Ab and Cry1Ac on HEK293 cell line. (A) Cells were treated with Roundup (1–20 000 ppm) and the mitochondrial respiration was measured through succinate dehydrogenase activity (left). The  $LC_{50}$  for Roundup was determined as 57.5 ppm by nonlinear regression (arrow). On the right, the adenylate kinase release showing membrane alterations by Roundup alone at its  $LC_{50}$  in comparison to control. (B) Combined effects of Roundup at its  $LC_{50}$  with *Bt* toxins measured on caspase 3/7 activities (%). The same tendency for the combined effects but with no significant results was detected on adenylate kinase release and succinate dehydrogenase; results not shown. Standard errors of the mean are indicated in all instances ( $n=9$ ). Significance of the effects (\*  $P < 0.05$ ; \*\*  $P < 0.01$ ) is tested against the negative control C (medium alone) or the positive Roundup control (R).

On two biomarkers of cell death, Cry1Ab exposure led to respiration inhibition and plasma membrane alterations, by contrast to Cry1Ac. This could be consistent with the fact that the consumption of MON810 maize producing Cry1Ab (in the ppm range) induced signs of hepatorenal alterations in a subchronic feeding study on rats (Spiroux de Vendômois *et al.*, 2009). It is known that both toxins differ significantly in their domain III structure (Karim and Dean, 2000), which is the only one to be involved at the same time in ion channel function, receptor binding and insertion into the membrane (Dean *et al.*, 1996). This occurred at relatively high concentrations (100 ppm) in comparison to the concentrations produced in GM plants (1–20 ppm, Székács *et al.*, 2010). The content can differ greatly according to the GM variety and environmental conditions (Then and Lorch, 2008). The exposure during consumption can appear low enough to avoid side effects, and whether this occurs *in vivo* remains to be checked. However, the bioaccumulation in tissues, or bioaccumulative or long-term effects, has to be taken into account since *Bt* residues were recently claimed to be measured in pregnant women's serum at around 0.2 ppb (Aris and Leblanc, 2011). In addition, high quantities of *Bt* crops can be consumed by mammals. The procedure for GMO market authorizations for crops such as MON810 (EFSA, 2009) does not require *in vitro* tests on human cells of *Bt* toxins, nor on its combinatorial effects, thus our results are raising new questions about the safety of these toxins and the *Bt* crops in general. Although *in vitro* studies suggest degradation in human gastric

secretions, digestion is never a complete process and insecticide toxins cannot be fully degraded *in vivo* (Paul *et al.*, 2010). This is known to be the case for Cry1Ab (Chowdhury *et al.*, 2003). It must be underlined that the insecticidal proteins produced by the GM plants are in soluble forms, and thus already biochemically activated, unlike those produced by the microorganism *Bt*, secreted as inactive precursors or protoxins (Hilbeck and Schmidt, 2006). The importance of *Bt* toxin activation has been demonstrated in relation to *in vitro* membrane damages of human erythrocytes, by solubilized *Bt* toxins, but not by the intact form (Rani and Balaraman, 1996). Cellular response to *Bt* toxins does not elicit apoptosis; it induces necrotic effects via a plasma membrane disruption for Cry1Ab within only 24 h. This may be due to pore formation like in insect cells owing to binding to specific receptors or membrane lipid rafts (Then, 2010; Soberón *et al.*, 2009).

We also demonstrated that Cry1Ab and Cry1Ac exposures slightly reduced caspase 3/7 activations induced by Roundup. This could be related at least in part to the properties of Roundup compounds, especially adjuvants. We observed previously, in our group, that serum delayed the cytotoxic effects induced by Roundup. This was probably due to serum binding proteins (Benachour *et al.*, 2007). Here we can assume that physico-chemical properties of proteins may give them the ability to bind and form complexes with Roundup adjuvants that have tendencies to form vesicles, buffering their bioavailability to cells. Similarly, a nonsignificant tendency of reduction of the cytotoxic effects of Roundup was observed on mitochondrial respiration and membrane degradation when the toxins were added. The apoptosis induction appeared to be the most sensitive impact of combined effects. This does not exclude other intracellular targets such as endocrine disruption, since Roundup is antiandrogenic from 0.5 ppm, below toxic levels and close to human serum levels (0.1–0.2 ppm in Acquavella *et al.*, 2004).

Here we documented that modified *Bt* toxins are not inert on human cells, but can exert toxicity, at least under certain *in vitro* conditions. *In vivo* implications should be now assessed. Our results raise new questions in the risk assessment of food and feed derived from genetically engineered plants.

### Acknowledgments

We are grateful to Testbiotech and the GEKKO Foundation, the association Denis Guichard, CRIIGEN and the Conseil Regional of Basse-Normandie for their support. R.M. and E.C. are recipients of fellowships from CRIIGEN and the Conseil Regional of Basse-Normandie. We would also like to thank Marianne Pusztai-Carey for one of the toxin preparations.

### REFERENCES

- Acquavella JF, Alexander BH, Mandel JS, Gustin C, Baker B, Chapman P, Bleeker M. 2004. Glyphosate biomonitoring for farmers and their families: results from the Farm Family Exposure Study. *Environ. Health Perspect.* **112**(3): 321–326.
- Aris A, Leblanc S. 2011. Maternal and fetal exposure to pesticides associated to genetically modified foods in Eastern Townships of Quebec, Canada. *Reprod. Toxicol.*, February 18.
- Arregui MC, Lenardon A, Sanchez D, Maitre MI, Scotta R, Enrique S. 2004. Monitoring glyphosate residues in transgenic glyphosate-resistant soybean. *Pest Manag. Sci.* **60**: 163–166.
- Benachour N, Séralini GE. 2009. Glyphosate formulations induce apoptosis and necrosis in human umbilical, embryonic, and placental cells. *Chem. Res. Toxicol.* **22**: 97–105.

- Benachour N, Sipahutar H, Moslemi S, Gasnier C, Travert C, Séralini GE. 2007. Time- and dose-dependent effects of roundup on human embryonic and placental cells. *Arch. Environ. Contam. Toxicol.* **53**: 126–133.
- Chowdhury EH, Shimada N, Murata H, Mikami O, Sultana P, Miyazaki S, Yoshioka M, Yamanaka N, Hirai N, Nakajima Y. 2003. Detection of Cry1Ab protein in gastrointestinal contents but not visceral organs of genetically modified Bt11-fed calves. *Vet. Hum. Toxicol.* **45**: 72–75.
- Cox C. 2004. Glyphosate. *J. Pest. Reform.* **24**: 10–15.
- Crouch SP, Kozłowski R, Slater KJ, Fletcher J. 1993. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. *J. Immunol. Meth.* **160**: 81–88.
- Dean DH, Rajamohan F, Lee MK, Wu SJ, Chen XJ, Alcántara E, Hussain SR. 1996. Probing the mechanism of action of *Bacillus thuringiensis* insecticidal proteins by site-directed mutagenesis – a minireview. *Gene* **179**(1): 111–117.
- EFSA. 2009. Scientific opinion on genetically modified organism MON810. *The EFSA J.* **1149**: 1–84.
- Gasnier C, Dumont C, Benachour N, Clair E, Chagnon MC, Séralini GE. 2009. Glyphosate-based herbicides are toxic and endocrine disruptors in human cell lines. *Toxicology* **262**: 184–191.
- George J, Prasad S, Mahmood Z, Shukla Y. 2010. Studies on glyphosate-induced carcinogenicity in mouse skin: a proteomic approach. *J. Proteom.* **73**: 951–964.
- Hilbeck A, Schmidt JEU. 2006. Another view on *Bt* proteins – how specific are they and what else might they do? *Biopest. Int.* **2**(1): 1–50.
- Ito A, Sasaguri Y, Kitada S, Kusaka Y, Kuwano K, Masutomi K, Mizuki E, Akao T, Ohba M. 2004. A *Bacillus thuringiensis* crystal protein with selective cytotoxic action to human cells. *J. Biol. Chem.* **279**: 21282–21286.
- James C. 2010. Global status of commercialized biotech/GM crops: 2010 ISAAA Brief 42.
- Karim S, Dean DH. 2000. Pesticidal and receptor binding properties of *Bacillus thuringiensis* Cry1Ab and Cry1Ac delta-endotoxin mutants to *Pectinophora gossypiella* and *Helicoverpa zea*. *Curr. Microbiol.* **41**(6): 430–440.
- Monosson E. 2005. Chemical mixtures: considering the evolution of toxicology and chemical assessment. *Environ. Health Perspect.* **113**: 383–390.
- Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Meth.* **65**: 55–63.
- Nagamatsu Y, Okamura S, Saitou H, Akao T, Mizuki E. 2010. Three Cry toxins in two types from *Bacillus thuringiensis* strain M019 preferentially kill human hepatocyte cancer and uterus cervix cancer cells. *Biosci. Biotechnol. Biochem.* **74**: 494–498.
- Paganelli A, Gnazzo V, Acosta H, Lopez SL, Carrasco AE. 2010. Glyphosate-based herbicides produce teratogenic effects on vertebrates by impairing retinoic acid signaling. *Chem. Res. Toxicol.* **23**: 1586–1595.
- Paul V, Guertler P, Wiedemann S, Meyer HH. 2010. Degradation of Cry1Ab protein from genetically modified maize (MON810) in relation to total dietary feed proteins in dairy cow digestion. *Transgenic Res.* **19**: 683–689.
- Pusztai-Carey M, Carey P, Lessard T, Yaguchi M. 1994. Isolation, quantitation and purification of insecticidal proteins from *Bacillus thuringiensis*. US patent 5,356,788.
- Rani SS, Balaraman K. 1996. Effect of insecticidal crystal proteins of *Bacillus thuringiensis* on human erythrocytes *in vitro*. *Indian J. Exp. Biol.* **34**: 1241–1244.
- Séralini GE, Spiroux de Vendômois J, Cellier D, Sultan C, Buiatti M, Gallagher L, Antoniou M, Dronamraju KR. 2009. How subchronic and chronic health effects can be neglected for GMOs, pesticides or chemicals. *Int. J. Biol. Sci.* **5**: 438–443.
- Séralini GE, Mesnage R, Clair E, Gress S, Cellier D, Spiroux de Vendômois J. 2011. Genetically modified crops safety assessments: present limits and possible improvements. *Environ. Sci. Eur.* **23**: 10.
- Singh A, Sivaprasad CV. 2009. Functional interpretation of APN receptor from *M. sexta* using a molecular model. *Bioinformation* **3**: 321–325.
- Soberón M, Gill SS, Bravo A. 2009. Signaling versus punching hole: how do *Bacillus thuringiensis* toxins kill insect midgut cells. *Cell Mol. Life Sci.* **66**: 1337–1349.
- Spiroux de Vendômois J, Roullier F, Cellier D, Séralini GE. 2009. A comparison of the effects of three GM corn varieties on mammalian health. *Int. J. Biol. Sci.* **5**: 706–726.

1	Spiroux de Vendômois J, Cellier D, Vélot C, Clair E, Mesnage R, Séralini GE. 2010. Debate on GMOs health risks after statistical findings in regulatory tests. <i>Int. J. Biol. Sci.</i> <b>6</b> : 590–598.	66
2		67
3	Székács A, Lauber E, Juracsek J, Darvas B. 2010. Cry1Ab toxin production of MON 810 transgenic maize. <i>Environ. Toxicol. Chem.</i> <b>29</b> : 182–190.	68
4		69
5		70
6	Tank JL, Rosi-Marshall EJ, Royer TV, Whiles MR, Griffiths NA, Frauendorf TC, Treering DJ. 2010. Occurrence of maize detritus and a transgenic insecticidal protein (Cry1Ab) within the stream network of an agricultural landscape. <i>Proc. Natl Acad. Sci. USA</i> <b>107</b> : 17645–17650.	71
7		72
8		73
9		74
10		75
11		76
12		77
13		78
14		79
15		80
16		81
17		82
18		83
19		84
20		85
21		86
22		87
23		88
24		89
25		90
26		91
27		92
28		93
29		94
30		95
31		96
32		97
33		98
34		99
35		100
36		101
37		102
38		103
39		104
40		105
41		106
42		107
43		108
44		109
45		110
46		111
47		112
48		113
49		114
50		115
51		116
52		117
53		118
54		119
55		120
56		121
57		122
58		123
59		124
60		125
61		126
62		127
63		128
64		129
65		130

# Author Query Form

---

**Journal: Journal of Applied Toxicology**

**Article: jat\_2712**

Dear Author,

During the copyediting of your paper, the following queries arose. Please respond to these by annotating your proofs with the necessary changes/additions.

- If you intend to annotate your proof electronically, please refer to the E-annotation guidelines.
- If you intend to annotate your proof by means of hard-copy mark-up, please refer to the proof mark-up symbols guidelines. If manually writing corrections on your proof and returning it by fax, do not write too close to the edge of the paper. Please remember that illegible mark-ups may delay publication.

Whether you opt for hard-copy or electronic annotation of your proofs, we recommend that you provide additional clarification of answers to queries by entering your answers on the query sheet, in addition to the text mark-up.


Query No.	Query	Remark
Q1	AUTHOR: Please supply short abstract of up to 80 words for table of contents.	
Q2	AUTHOR: The citation "Paul et al. 2009" (original) has been changed to "Paul et al., 2010". Please check if appropriate.	
Q3	AUTHOR: Aris and Leblanc 2011, please update.	
Q4	AUTHOR: Figures 1 and 2 contains poor quality of text and overlapping data. Please correct and resupply figures with better quality.	

USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION


Required software to e-Annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 8.0 or above). (Note that this document uses screenshots from Adobe Reader X)

The latest version of Acrobat Reader can be downloaded for free at: <http://get.adobe.com/reader/>

Once you have Acrobat Reader open on your computer, click on the [Comment](#) tab at the right of the toolbar:



This will open up a panel down the right side of the document. The majority of tools you will use for annotating your proof will be in the [Annotations](#) section, pictured opposite. We've picked out some of these tools below:



**1. Replace (Ins) Tool – for replacing text.**




Strikes a line through text and opens up a text box where replacement text can be entered.

**How to use it**

- Highlight a word or sentence.
- Click on the [Replace \(Ins\)](#) icon in the Annotations section.
- Type the replacement text into the blue box that appears.

standard framework for the analysis of microeconomics. Nevertheless, it also led to the emergence of a new paradigm of strategic behaviour. The number of competitors in the industry is that the structure of the market is a key component. The main components of the market are, at the micro level, are externalities and public goods. Important works on this subject by Shirasaka (1987) and henceforth) we open the 'black b



**2. Strikethrough (Del) Tool – for deleting text.**



Strikes a red line through text that is to be deleted.

**How to use it**

- Highlight a word or sentence.
- Click on the [Strikethrough \(Del\)](#) icon in the Annotations section.

there is no room for extra profits and the number of competitors are zero and the number of firms (net) values are not determined by the number of firms. Blanchard and Kiyotaki (1987), in their paper on perfect competition in general equilibrium, show that the effects of aggregate demand and supply shocks in a classical framework assuming monopolistic competition are an exogenous number of firms

**3. Add note to text Tool – for highlighting a section to be changed to bold or italic.**



Highlights text in yellow and opens up a text box where comments can be entered.

**How to use it**

- Highlight the relevant section of text.
- Click on the [Add note to text](#) icon in the Annotations section.
- Type instruction on what should be changed regarding the text into the yellow box that appears.

dynamic responses of mark-ups consistent with the VAR evidence

sation of the market with well-labelled demand curves. The number of competitors and the impact on the market is that the demand-



**4. Add sticky note Tool – for making notes at specific points in the text.**




Marks a point in the proof where a comment needs to be highlighted.

**How to use it**

- Click on the [Add sticky note](#) icon in the Annotations section.
- Click at the point in the proof where the comment should be inserted.
- Type the comment into the yellow box that appears.

and supply shocks. Most of the time, the number of firms in the industry is that the structure of the sector is that the structure of the sector



USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION


**5. Attach File Tool – for inserting large amounts of text or replacement figures.**



Inserts an icon linking to the attached file in the appropriate place in the text.

**How to use it**

- Click on the [Attach File](#) icon in the Annotations section.
- Click on the proof to where you'd like the attached file to be linked.
- Select the file to be attached from your computer or network.
- Select the colour and type of icon that will appear in the proof. Click OK.



**6. Add stamp Tool – for approving a proof if no corrections are required.**




Inserts a selected stamp onto an appropriate place in the proof.

**How to use it**

- Click on the [Add stamp](#) icon in the Annotations section.
- Select the stamp you want to use. (The [Approved](#) stamp is usually available directly in the menu that appears).
- Click on the proof where you'd like the stamp to appear. (Where a proof is to be approved as it is, this would normally be on the first page).

of the business cycle, starting with the  
 on perfect competition, constant ret  
 production. In this environment goods  
 extra profits and the market for marke  
 he market for goods is determined by the model. The New-Key  
 otaki (1987), has introduced produc  
 general equilibrium models with nomin  
 and... Most of this literature

**APPROVED**




**7. Drawing Markups Tools – for drawing shapes, lines and freeform annotations on proofs and commenting on these marks.**


Allows shapes, lines and freeform annotations to be drawn on proofs and for comment to be made on these marks..

**How to use it**

- Click on one of the shapes in the [Drawing Markups](#) section.
- Click on the proof at the relevant point and draw the selected shape with the cursor.
- To add a comment to the drawn shape, move the cursor over the shape until an arrowhead appears.
- Double click on the shape and type any text in the red box that appears.



For further information on how to annotate proofs, click on the [Help](#) menu to reveal a list of further options:







## WILEY AUTHOR DISCOUNT CLUB

We would like to show our appreciation to you, a highly valued contributor to Wiley's publications, by offering a **unique 25% discount** off the published price of any of our books\*.

All you need to do is apply for the **Wiley Author Discount Card** by completing the attached form and returning it to us at the following address:

The Database Group (Author Club)  
John Wiley & Sons Ltd  
The Atrium  
Southern Gate  
Chichester  
PO19 8SQ  
UK

Alternatively, you can **register online** at [www.wileyeurope.com/go/authordiscount](http://www.wileyeurope.com/go/authordiscount)  
Please pass on details of this offer to any co-authors or fellow contributors.

After registering you will receive your Wiley Author Discount Card with a special promotion code, which you will need to quote whenever you order books direct from us.

The quickest way to order your books from us is via our European website at:

**<http://www.wileyeurope.com>**

Key benefits to using the site and ordering online include:

- Real-time SECURE on-line ordering
- Easy catalogue browsing
- Dedicated Author resource centre
- Opportunity to sign up for subject-orientated e-mail alerts

Alternatively, you can order direct through Customer Services at:  
[cs-books@wiley.co.uk](mailto:cs-books@wiley.co.uk), or call +44 (0)1243 843294, fax +44 (0)1243 843303


So take advantage of this great offer and return your completed form today.

Yours sincerely,

Verity Leaver  
Group Marketing Manager  
[author@wiley.co.uk](mailto:author@wiley.co.uk)

### \*TERMS AND CONDITIONS

This offer is exclusive to Wiley Authors, Editors, Contributors and Editorial Board Members in acquiring books for their personal use. There must be no resale through any channel. The offer is subject to stock availability and cannot be applied retrospectively. This entitlement cannot be used in conjunction with any other special offer. Wiley reserves the right to amend the terms of the offer at any time.




# REGISTRATION FORM

## For Wiley Author Club Discount Card

To enjoy your 25% discount, tell us your areas of interest and you will receive relevant catalogues or leaflets from which to select your books. Please indicate your specific subject areas below.

<p><b>Accounting</b> <input type="checkbox"/></p> <p>Public <input type="checkbox"/></p> <p>Corporate <input type="checkbox"/></p> <p><b>Chemistry</b> <input type="checkbox"/></p> <p>Analytical <input type="checkbox"/></p> <p>Industrial/Safety <input type="checkbox"/></p> <p>Organic <input type="checkbox"/></p> <p>Inorganic <input type="checkbox"/></p> <p>Polymer <input type="checkbox"/></p> <p>Spectroscopy <input type="checkbox"/></p> <p><b>Encyclopedia/Reference</b> <input type="checkbox"/></p> <p>Business/Finance <input type="checkbox"/></p> <p>Life Sciences <input type="checkbox"/></p> <p>Medical Sciences <input type="checkbox"/></p> <p>Physical Sciences <input type="checkbox"/></p> <p>Technology <input type="checkbox"/></p> <p><b>Earth &amp; Environmental Science</b> <input type="checkbox"/></p> <p><b>Hospitality</b> <input type="checkbox"/></p> <p><b>Genetics</b> <input type="checkbox"/></p> <p>Bioinformatics/ Computational Biology <input type="checkbox"/></p> <p>Proteomics <input type="checkbox"/></p> <p>Genomics <input type="checkbox"/></p> <p>Gene Mapping <input type="checkbox"/></p> <p>Clinical Genetics <input type="checkbox"/></p> <p><b>Medical Science</b> <input type="checkbox"/></p> <p>Cardiovascular <input type="checkbox"/></p> <p>Diabetes <input type="checkbox"/></p> <p>Endocrinology <input type="checkbox"/></p> <p>Imaging <input type="checkbox"/></p> <p>Obstetrics/Gynaecology <input type="checkbox"/></p> <p>Oncology <input type="checkbox"/></p> <p>Pharmacology <input type="checkbox"/></p> <p>Psychiatry <input type="checkbox"/></p> <p><b>Non-Profit</b> <input type="checkbox"/></p>	<p><b>Architecture</b> <input type="checkbox"/></p> <p><b>Business/Management</b> <input type="checkbox"/></p> <p><b>Computer Science</b> <input type="checkbox"/></p> <p>Database/Data Warehouse <input type="checkbox"/></p> <p>Internet Business <input type="checkbox"/></p> <p>Networking <input type="checkbox"/></p> <p>Programming/Software Development <input type="checkbox"/></p> <p>Object Technology <input type="checkbox"/></p> <p><b>Engineering</b> <input type="checkbox"/></p> <p>Civil <input type="checkbox"/></p> <p>Communications Technology <input type="checkbox"/></p> <p>Electronic <input type="checkbox"/></p> <p>Environmental <input type="checkbox"/></p> <p>Industrial <input type="checkbox"/></p> <p>Mechanical <input type="checkbox"/></p> <p><b>Finance/Investing</b> <input type="checkbox"/></p> <p>Economics <input type="checkbox"/></p> <p>Institutional <input type="checkbox"/></p> <p>Personal Finance <input type="checkbox"/></p> <p><b>Life Science</b> <input type="checkbox"/></p> <p><b>Landscape Architecture</b> <input type="checkbox"/></p> <p><b>Mathematics Statistics</b> <input type="checkbox"/></p> <p><b>Manufacturing</b> <input type="checkbox"/></p> <p><b>Materials Science</b> <input type="checkbox"/></p> <p><b>Psychology</b> <input type="checkbox"/></p> <p>Clinical <input type="checkbox"/></p> <p>Forensic <input type="checkbox"/></p> <p>Social &amp; Personality <input type="checkbox"/></p> <p>Health &amp; Sport <input type="checkbox"/></p> <p>Cognitive <input type="checkbox"/></p> <p>Organizational <input type="checkbox"/></p> <p>Developmental &amp; Special Ed <input type="checkbox"/></p> <p>Child Welfare <input type="checkbox"/></p> <p>Self-Help <input type="checkbox"/></p> <p><b>Physics/Physical Science</b> <input type="checkbox"/></p>
--	--

Please complete the next page /





I confirm that I am (\*delete where not applicable):

a **Wiley** Book Author/Editor/Contributor\* of the following book(s):

ISBN:

ISBN:

a **Wiley** Journal Editor/Contributor/Editorial Board Member\* of the following journal(s):

SIGNATURE: ..... Date: .....

**PLEASE COMPLETE THE FOLLOWING DETAILS IN BLOCK CAPITALS:**

TITLE: (e.g. Mr, Mrs, Dr) ..... FULL NAME: .....

JOB TITLE (or Occupation): .....

DEPARTMENT: .....

COMPANY/INSTITUTION: .....

ADDRESS: .....

.....

TOWN/CITY: .....

COUNTY/STATE: .....

COUNTRY: .....

POSTCODE/ZIP CODE: .....

DAYTIME TEL: .....

FAX: .....

E-MAIL: .....

**YOUR PERSONAL DATA**

We, John Wiley & Sons Ltd, will use the information you have provided to fulfil your request. In addition, we would like to:

- 1. Use your information to keep you informed by post of titles and offers of interest to you and available from us or other Wiley Group companies worldwide, and may supply your details to members of the Wiley Group for this purpose. [ ] Please tick the box if you do **NOT** wish to receive this information
- 2. Share your information with other carefully selected companies so that they may contact you by post with details of titles and offers that may be of interest to you. [ ] Please tick the box if you do **NOT** wish to receive this information.

**E-MAIL ALERTING SERVICE**

We also offer an alerting service to our author base via e-mail, with regular special offers and competitions. If you **DO** wish to receive these, please opt in by ticking the box [ ].

If, at any time, you wish to stop receiving information, please contact the Database Group ([databasegroup@wiley.co.uk](mailto:databasegroup@wiley.co.uk)) at John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, PO19 8SQ, UK.

**TERMS & CONDITIONS**

This offer is exclusive to Wiley Authors, Editors, Contributors and Editorial Board Members in acquiring books for their personal use. There should be no resale through any channel. The offer is subject to stock availability and may not be applied retrospectively. This entitlement cannot be used in conjunction with any other special offer. Wiley reserves the right to vary the terms of the offer at any time.

**PLEASE RETURN THIS FORM TO:**

Database Group (Author Club), John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, PO19 8SQ, UK [author@wiley.co.uk](mailto:author@wiley.co.uk)  
Fax: +44 (0)1243 770154

